Aurobindo Pharma Balance Sheet Health
Financial Health criteria checks 6/6
Aurobindo Pharma has a total shareholder equity of ₹298.5B and total debt of ₹63.2B, which brings its debt-to-equity ratio to 21.2%. Its total assets and total liabilities are ₹450.7B and ₹152.2B respectively. Aurobindo Pharma's EBIT is ₹43.2B making its interest coverage ratio 14.9. It has cash and short-term investments of ₹63.3B.
Key information
21.2%
Debt to equity ratio
₹63.15b
Debt
Interest coverage ratio | 14.9x |
Cash | ₹63.29b |
Equity | ₹298.51b |
Total liabilities | ₹152.21b |
Total assets | ₹450.72b |
Recent financial health updates
Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet
Dec 27Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?
Jun 14Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly
Jan 09We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt
Jun 20These 4 Measures Indicate That Aurobindo Pharma (NSE:AUROPHARMA) Is Using Debt Reasonably Well
Nov 27Recent updates
Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271
May 29Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value
May 22Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors
Apr 10Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?
Jan 14Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet
Dec 27Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value
Sep 07Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?
Jun 14Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?
May 21Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price
Feb 11Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly
Jan 09Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?
Nov 02We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt
Jun 20Calculating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)
Apr 14Aurobindo Pharma's (NSE:AUROPHARMA) Dividend Will Be ₹1.50
Feb 11Calculating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)
Jan 08These 4 Measures Indicate That Aurobindo Pharma (NSE:AUROPHARMA) Is Using Debt Reasonably Well
Nov 27Aurobindo Pharma's (NSE:AUROPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Nov 10Financial Position Analysis
Short Term Liabilities: AUROPHARMA's short term assets (₹242.1B) exceed its short term liabilities (₹122.0B).
Long Term Liabilities: AUROPHARMA's short term assets (₹242.1B) exceed its long term liabilities (₹30.2B).
Debt to Equity History and Analysis
Debt Level: AUROPHARMA has more cash than its total debt.
Reducing Debt: AUROPHARMA's debt to equity ratio has reduced from 49.7% to 21.2% over the past 5 years.
Debt Coverage: AUROPHARMA's debt is well covered by operating cash flow (38.6%).
Interest Coverage: AUROPHARMA's interest payments on its debt are well covered by EBIT (14.9x coverage).